Oxaliplatin — Drug Intelligence | 223 EU Trials

Filter these 223 trials by condition, phase, country and more.

Open in Search →

223 Registered trials

108 Recruiting

86 Completed trials

117 Sponsors

24 Countries

Phase III

Phase II

Phase III: 83 Phase II/III: 15 Phase II: 94 Phase I/II: 17 Phase III/IV: 2 Phase IV: 6 Phase I (Other): 1 Phase I (FiH): 5

Oversight events:

8 serious breaches 15 temporary halts 5 urgent safety measures 17 unexpected events 11 corrective measures across 24 trials

View oversight register →

Indications tested

Colorectal cancer metastatic 8 Colorectal cancer 7 Gastric cancer 6 Gastrooesophageal cancer 6 Rectal cancer 5 Adenocarcinoma gastric 4 Colorectal cancer stage III 4 Colorectal cancer stage II 3 Metastatic gastric cancer 3 Diffuse large B-cell lymphoma 3 HER2 positive gastric cancer 3 Pancreatic carcinoma metastatic 2

Sponsors using this IMP

Unicancer 13 Merck Sharp & Dohme LLC 11 Fondation Franc.Cancerologie Digestive 9 AstraZeneca AB 7 Centre Hospitalier Universitaire De Dijon 6 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 6 Fondazione GONO G.I. 6 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 6 Catharina Ziekenhuis Stichting 5 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 5 IRCCS Istituto Nazionale Tumori Fondazione Pascale 5 AbbVie Deutschland GmbH & Co. KG 4

All trials — page 4

223 total

ANALYSIS OF EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED COLON CANCER. Recruiting

2024-519825-39-00 Phase II 1 country Clinica Universidad De Navarra
Exploratory Study of CAPEcitabine pharmacokinetics and hand-foot syndrome in CES1 variant carriers: the ESCAPE study Recruiting

2024-516788-96-00 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Dose individualization of chemotherapy in patients with gastrointestinal cancers lacking a specific liver enzyme Recruiting

2023-509963-25-00 Phase II 1 country Unicancer
REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemoth… Recruiting

2024-516709-22-00 Phase II/III 1 country Centre Hospitalier Regional Universitaire
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting

2023-508724-35-00 Phase II 1 country Unicancer
Prospective phase IIb study to evaluate the efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic can… Recruiting

2024-519067-17-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 … Recruiting

2024-513441-36-00 Phase II 3 countries Glaxosmithkline Research & Development Limited
Phase II Study of Avelumab plus chemotherapy for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC). Mo… Recruiting

2024-516777-77-00 Phase II 1 country Vall D Hebron Institute Of Oncology
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRES… Recruiting

2023-506632-32-00 Phase III 1 country Fondazione GONO G.I.
Timing of start of systemlc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preferenc… Recruiting

2023-509465-20-00 Phase III 1 country Amsterdam UMC
A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi… Recruiting

2023-509851-15-00 Phase III 3 countries Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 Phase II 1 country Centre Hospitalier Universitaire De Dijon
DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting

2023-506115-17-00 Phase III 1 country Academisch Ziekenhuis Leiden
Can we Save the rectum by watchful waiting or transanal surgery following short- or long-course radioTherapy and Additional local oR systemi… Recruiting

2024-514620-17-00 Phase II 1 country Radboud universitair medisch centrum Stichting
The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Quality of Life Recruiting

2024-513437-21-00 Phase IV 1 country Turku University Hospital
Substudy 06C: Combination Therapies in Gastroesophageal Adenocarcinoma Recruiting

2023-509307-33-00 Phase I/II 4 countries Merck Sharp & Dohme LLC
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge… Recruiting

2024-511070-68-01 Phase III 1 country Centre Hospitalier Universitaire De Dijon
PREOPANC-5 Recruiting

2023-508707-20-00 Phase I/II 1 country Amsterdam UMC
Personalized dosing of FOLFIRINOX in pancreatic cancer patients: a phase-2 pharmacokinetic, safety and feasibility trial Recruiting

2024-510576-21-00 Phase II 1 country Catharina Ziekenhuis Stichting
Prospective study in patients with colon or rectum cancer with liver metastasis of the efficacy and toxicity of standard therapy (chemothera… Recruiting

2024-517204-11-00 Phase II 1 country Fondation Franc.Cancerologie Digestive
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 Phase III 1 country Centre Hospitalier Universitaire De Dijon
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 Phase II 1 country Fondation Franc.Cancerologie Digestive
Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI Recruiting

2023-505298-34-00 Phase II 1 country Unicancer
PRODIGE 87 FOXTROT II : Personalising and refining neo-adjuvant chemotherapy in locally advanced but resectable colon cancer in the elderly … Recruiting

2023-505214-23-00 Phase III 1 country Centre Hospitalier Universitaire De Dijon

Showing 73–96 of 223 trials

← All drugs A–Z